Scientists at the University of Oxford, led by Professor Ahmed Ahmed, are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
In this study, the CRUK-funded researchers will establish the targets for the vaccine. They will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids.
If this research is successful, work will then begin on clinical trials of the vaccine. The hope is that in the future, women could be offered this vaccine to prevent ovarian cancer in the first place.
Read the full story on the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) website.
more recommended stories
Higher BMI and Hypothyroidism Risk StudyA major longitudinal study from Canada.
Therapeutic Plasma Exchange Reduces Biological AgeTherapeutic plasma exchange (TPE), especially when.
Childhood Cancer Diagnosis Delays PersistDelays in childhood cancer diagnosis remain.
Hypothalamic Changes in Eating Disorders ExplainedGroundbreaking MRI scans reveal microstructural hypothalamic.
Rapid Blood Test for Rare Diseases Revolutionizes Pediatric DiagnosisA groundbreaking blood test developed by.
Blood Markers for Teen Depression: A Breakthrough in Early DetectionMental health professionals and researchers have.
Long-Term Antidepressant Use Increases Withdrawal RiskA new study led by researchers.
Cell Painting Identifies Flavonoids for Bladder CancerIn a breakthrough led by Baylor.
Young Adult Cancer Survivors Mental Health StrugglesNew research from the University of.
Lecanemab Access Disparities Limit EquityLecanemab access disparities are raising red.
Leave a Comment